Amgen: Humira Interchangeability ‘A Nice To Have, Not A Need To Have’
‘Many’ Biosimilars Sponsors ‘Struggled’ With Key Issue Of Continuous Supply
Executive Summary
Amgen management spoke at length about biosimilars during the company’s two-and-a-half-hour-long business review meeting, with the launch of its Amjevita (adalimumab-atto) biosimilar now less than a year away.
You may also be interested in...
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?